The discipline of pharmacogenetics (PGx) offers substantial potential for advancing individualized healthcare by tailoring drug therapy to a patient’s genetic profile. Although PGx provides clear clinical advantages, its broader adoption is still restricted by financial, ethical, and organizational obstacles within our healthcare system. To evaluate the influence of pharmacogenetic testing, we conducted a retrospective review of anonymized electronic health record data from a heterogeneous patient cohort, examining key factors such as prescribing behavior and genotyping outcomes. Additionally, a direct comparison with activity reported a decade earlier from the same PGx laboratory was carried out to measure long-term progress. The review showed extensive real-world use of PGx testing, with 1,145 tests conducted over a single year and representing a 35% rise throughout the study period. Among the 17 medical specialties ordering PGx analyses, Oncology contributed the largest proportion, with 58.47% of all individuals tested. In total, 1,000 tests were ordered for patients who could require genotype-dependent dose modifications, and 76 patients eventually received dose changes informed by their genetic results. This work delivers an in-depth descriptive summary of routine data produced in a public, tertiary-level pharmacogenetics laboratory and strongly supports incorporating PGx testing into everyday patient care.
